Redx snags potential $377M deal with Astrazeneca for fibrosis-targeting RXC-006 Aug. 4, 2020 By Nuala Moran LONDON – Redx Pharma plc is in the process of handing its RXC-006 program over to Astrazeneca plc, after signing a potential $377 million development and commercialization deal for the porcupine inhibitor in the treatment of fibrotic disease.Read More
RSS